{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Nintedanib+%28BIBF1120%29&page=2",
    "query": {
      "intervention": "Nintedanib (BIBF1120)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 70,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Nintedanib+%28BIBF1120%29&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Nintedanib+%28BIBF1120%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T16:18:22.901Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03820726",
      "title": "A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lung Diseases, Interstitial"
      ],
      "interventions": [
        {
          "name": "Nintedanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 435,
      "start_date": "2019-04-16",
      "completion_date": "2022-08-30",
      "has_results": true,
      "last_update_posted_date": "2023-09-13",
      "last_synced_at": "2026-10-09T16:18:22.901Z",
      "location_count": 33,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Sacramento, California + 25 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03820726"
    },
    {
      "nct_id": "NCT02788474",
      "title": "Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Idiopathic Pulmonary Fibrosis"
      ],
      "interventions": [
        {
          "name": "nintedanib",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 347,
      "start_date": "2016-06-09",
      "completion_date": "2018-06-08",
      "has_results": true,
      "last_update_posted_date": "2023-12-21",
      "last_synced_at": "2026-10-09T16:18:22.901Z",
      "location_count": 8,
      "location_summary": "Jasper, Alabama • Danbury, Connecticut • Clearwater, Florida + 5 more",
      "locations": [
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Danbury",
          "state": "Connecticut"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02788474"
    },
    {
      "nct_id": "NCT01907100",
      "title": "Nintedanib (BIBF 1120) in Mesothelioma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Mesothelioma"
      ],
      "interventions": [
        {
          "name": "Nintedanib",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 545,
      "start_date": "2013-09-19",
      "completion_date": "2018-08-31",
      "has_results": true,
      "last_update_posted_date": "2019-03-18",
      "last_synced_at": "2026-10-09T16:18:22.901Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Littleton, Colorado + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Littleton",
          "state": "Colorado"
        },
        {
          "city": "Henderson",
          "state": "Nevada"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01907100"
    },
    {
      "nct_id": "NCT01979952",
      "title": "Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Idiopathic Pulmonary Fibrosis"
      ],
      "interventions": [
        {
          "name": "Matching Placebo",
          "type": "DRUG"
        },
        {
          "name": "Nintedanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 113,
      "start_date": "2013-11-26",
      "completion_date": "2016-10-27",
      "has_results": true,
      "last_update_posted_date": "2018-04-17",
      "last_synced_at": "2026-10-09T16:18:22.901Z",
      "location_count": 11,
      "location_summary": "Danbury, Connecticut • Sarasota, Florida • Skokie, Illinois + 8 more",
      "locations": [
        {
          "city": "Danbury",
          "state": "Connecticut"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Skokie",
          "state": "Illinois"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01979952"
    },
    {
      "nct_id": "NCT07344558",
      "title": "A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Idiopathic Pulmonary Fibrosis (IPF)"
      ],
      "interventions": [
        {
          "name": "MNKD-201(Nintedanib DPI)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mannkind Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "40 Years to 85 Years"
      },
      "enrollment_count": 27,
      "start_date": "2025-12-22",
      "completion_date": "2026-06-17",
      "has_results": false,
      "last_update_posted_date": "2026-07-22",
      "last_synced_at": "2026-10-09T16:18:22.901Z",
      "location_count": 9,
      "location_summary": "Fresno, California • Palm Springs, California • Doral, Florida + 5 more",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        },
        {
          "city": "Doral",
          "state": "Florida"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07344558"
    },
    {
      "nct_id": "NCT02299141",
      "title": "Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung",
        "Non-Small Cell Lung Cancer",
        "Nonsmall Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Nintedanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2015-05-07",
      "completion_date": "2025-04-23",
      "has_results": true,
      "last_update_posted_date": "2025-06-24",
      "last_synced_at": "2026-10-09T16:18:22.901Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02299141"
    },
    {
      "nct_id": "NCT05779007",
      "title": "Dose Reduction and Discontinuation With Anti-Fibrotic Medications",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Idiopathic Pulmonary Fibrosis"
      ],
      "interventions": [
        {
          "name": "Pirfenidone",
          "type": "DRUG"
        },
        {
          "name": "Nintedanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2778,
      "start_date": "2023-04-18",
      "completion_date": "2023-07-14",
      "has_results": true,
      "last_update_posted_date": "2025-07-28",
      "last_synced_at": "2026-10-09T16:18:22.901Z",
      "location_count": 1,
      "location_summary": "Ridgefield, Connecticut",
      "locations": [
        {
          "city": "Ridgefield",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05779007"
    },
    {
      "nct_id": "NCT02399215",
      "title": "Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carcinoid Tumor",
        "Metastatic Carcinoid Tumor",
        "Neuroendocrine Neoplasm"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nintedanib",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2015-05-15",
      "completion_date": "2022-08-31",
      "has_results": true,
      "last_update_posted_date": "2023-12-26",
      "last_synced_at": "2026-10-09T16:18:22.901Z",
      "location_count": 2,
      "location_summary": "Buffalo, New York • Columbus, Ohio",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02399215"
    },
    {
      "nct_id": "NCT06568458",
      "title": "A Study to Assess the Extent of Drug Interaction Between BMS-986278 and Nintedanib, the Relative Bioavailability of BMS-986278 in Tablet and the Effect That Food Has on BMS-986278 in Tablet Formulations in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "Nintedanib",
          "type": "DRUG"
        },
        {
          "name": "BMS 986278",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 71,
      "start_date": "2024-09-19",
      "completion_date": "2025-02-27",
      "has_results": false,
      "last_update_posted_date": "2025-03-14",
      "last_synced_at": "2026-10-09T16:18:22.901Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06568458"
    },
    {
      "nct_id": "NCT05497284",
      "title": "To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Idiopathic Pulmonary Fibrosis"
      ],
      "interventions": [
        {
          "name": "LTP001",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care (SoC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "40 Years to 100 Years"
      },
      "enrollment_count": 46,
      "start_date": "2022-11-10",
      "completion_date": "2024-09-26",
      "has_results": true,
      "last_update_posted_date": "2026-01-13",
      "last_synced_at": "2026-10-09T16:18:22.901Z",
      "location_count": 2,
      "location_summary": "Birmingham, Alabama • Kansas City, Kansas",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05497284"
    }
  ]
}